The Measurement of Health-related Quality of Life in Dermatology – Full Reference List

Summary of relevant publications by A Y Finlay & Colleagues

Original Research

Finlay AY, Kelly SE. Psoriasis – an index of disability. Clin Exp Dermatol, 1987; l2: 8-ll.

Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol, 1989; 14: 194-198.

Eun HC, Finlay AY. Measurement of atopic dermatitis disability. Annals of Dermatology, 1990; 2: 9-12.

Dooley G, Finlay AY. Personal construct systems of psoriatic patients. Clin Exp Dermatol, 1990; 15: 401-405.

Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol, 1990; 123: 751-756.

Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol, 1992; 17: 1-3.

Long CC, Funnell CM, Collard R, Finlay AY. What do members of the National Eczema Society really want? Clin Exp Dermatol, 1993; 18: 516-522.

Salek MS, Finlay AY, Luscombe DK, Allen BR, Berth-Jones J, Camp RDR, Graham-Brown RAC, Khan GK, Marks R, Motley RJ, Ross JS, Sowden JM. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. Br J Dermatol 1993; 129: 422-430.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use.
Clin Exp Dermatol, 1994; 19: 210-216.

Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol, 1995; 132: 236-244.

Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol, 1995; 132: 942-949.

Kurwa H, Finlay AY. Dermatology inpatient admission greatly improves life quality. Br J Dermatol, 1995; 133: 575-578.

Salek MS, Khan GK, Finlay AY. Questionnaire techniques in assessing acne handicap: reliability and validity study. Quality of Life Research, 1996;5: 131-138.

Blackford S, Roberts DL, Salek MS, Finlay AY. Basal cell carcinomas cause little handicap. Quality of Life Research, 1996; 5: 191-194.

Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporine in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol, 1996; 34: 1016-1021.

Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol, 1996; 7: 149-154.

Harris A, Burge SM, Dykes PJ, Finlay AY. Handicap in Darier’s disease and Hailey-Hailey disease. Br J Dermatol, 1996; 135: 959-963.

Blackford S, Finlay AY, Roberts DL. Quality of life in Behcet’s Syndrome: 335 patients surveyed. Br J Dermatol, 1997; 136: 293.

Newton JN, Mallon E, Klassen A, Ryan TJ, Finlay A. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol, 1997; 137: 563-567.

Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol, 1998; 138: 107-113.

Grosshans E, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M, Finlay AY, Soto P, Poncet M, Verschoore M, Clucas A.Evaluation of clinical efficacy and safety of adalpalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol, 1998; 139 (Suppl 52): 26-33.

Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. BrJ Dermatol, 1999; 140: 672-676.

Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, Finlay AY et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol, 2000; 142: 52-58.

Ayyalaraju RS, Finlay AY. Inpatient Dermatology: United Kingdom and United States similarities. Chapter in Dermatologic clinics: Inpatient dermatology. Eds: FA Kerdel, RS Kirsner, Dermatologic Clinics 2000; 18(3): 397-404.

Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000; 143: 979-982.

Lewis-Jones MS, Finlay AY, Dykes PJ. The Infant’s Dermatitis Quality of Life Index. Br J Dermatol, 2001; 144: 104-110.

Touw CR, Hakkaart-Van Roisen L, Verboom P, Paul C, Rutten FFH, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144:967-972.

Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2001; 15: 137-139.

Hermansen SE, Helland CA, Finlay AY. Patients’ and doctors’ assessment of skin disease handicap. Clin Exp Dermatology 2002; 27: 249-250.

Fivenson D, Arnold R J G, Kaniecki D J, Cohen J L, Frech F, Finlay A Y. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. J Managed Care Pharmacy 2002; 8 (5): 333-342.

Salek M S, Finlay A Y. Quality of Life in patients with severe psoriasis receiving cyclosporin: a multi-centre study. J Applied Therapeutic Research 2003; 4: 3-10.

Holme S A, Mann I, Sharpe J L, Dykes P J, Lewis-Jones M S, Finlay A Y. The Childrens’ Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003; 148: 285-290.

Loo W-J, Diba V, Chawla M, Finlay A Y. Dermatology Life Quality Index: influence of an illustrated version.
Br J Dermatol 2003; 148: 279-284.

Finlay A Y, Salek M S, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206(4): 307-315.

Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kirsner R S, Kerdel F A. Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: A comparative study. JAAD 2003; 49: 249-254.

Salek M S, Finlay A Y, Lewis J J C, Sumner M I. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral®). Quality of Life Research 2004; 13: 91-95.

Szepietowski J, Salomon J, Finlay A Y, Klepacki A, Chodynicka B, Marioneau N, Taieb C, Myon E. 
Dermatology Life Quality Index: Polish Version.
 Dermatologia Kliniczna 2004; 6: 63-70.

Dreno B, Finlay A Y, Nocera T, Verriere F, Taieb C, Myon E. CADI: Cultural and linguistic validation into French of an acne disability index,
Dermatology 2004; 208: 104-108.

Lewis V, Finlay A Y. Ten years experience of the Dermatology Life Quality Index (DLQI) J Investig Dermatol Symp Proc 2004; 9(2):169-180.

Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay A Y. DLQI scores in vitiligo: reliability and validity of the Persian Version.BMC Dermatology 2004; 4: 8.

Katugampola R P, Hongbo Y, Finlay A Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. BJD 20005; 152: 1256-1262.

Hongbo Y , Thomas C L, Harrison M A, Salek M S, Finlay A Y. Translating the science of quality of life into practice: what do DLQI scores mean? JID 2005; 125: 659-664.

David S E, Ahmed Z, Salek M S, Finlay A Y. Does enough quality of life related discussion occur during dermatology outpatient consultations? BJD 2005; 153: 997-1000.

Krueger G G, Langley R G, Finlay A Y, Griffiths C E M, Woolley J M, Lalla D, Jahreis A. Patient-reported outcomes of psoriasis improvement with etanercept therapy; results of a randomized phase II trial. BJD 2005; 153: 1192-1199.

Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN, Erythropoetic protoporphyria in the UK: Clinical features and effect on quality of life. Br J Dermatol 2006; 155: 374-381.

Takahashi N, Suzukamo Y, Natamura M, Miyachi Y, Green J, Ohya Y, Finlay A Y, Fukuhara S. Japanese version of the Dermatology Life Quality Index : Validity and reliability in patients with acne. Health Qual Life Outcomes 2006: 4(1): 46 (e-pub).

Basra M K A, Sue-Ho R, Finlay A Y.  The Family Dermatology Life Quality Index:  measuring the secondary impact of skin disease.  British Journal of Dermatology 2007; 156: 528-538 Erratum:  British Journal of Dermatology 2007; 156: 791

Katugampola R P, Lewis V J, Finlay A Y.  The Dermatology Life Quality Index:  assessing the efficacy of biological therapies for psoriasis.  British Journal of Dermatology 2007; 156: 945-950

Basra M K A, Finlay A Y.  The family impact of skin disease:  the Greater Patient concept.
British Journal of Dermatology 2007; 156: 929-937.

Eghlileb A M, Davies E E G, Finlay A Y.  Psoriasis has a major secondary impact on the lives of psoriasis family members and partners.  British Journal of Dermatology 2007; 156: 1245-1250

Misery L, Finlay A Y, Martin N, Boussetta S, Nguyen C, Myon E, Taieb C.  Atopic Dermatitis:  impact on the quality of life of patients and their partners.  Dermatology 2007; 215: 123-129

Salek S, Roberts A, Finlay A Y.  The practical reality of using a patient reported outcome measure in a routine dermatology clinic.  Dermatology 2007; 215: 315-319

Davies E, Patel C, Salek M S, Finlay A Y.  Does ad-hoc quality of life discussion in inflammatory skin disease consultations reflect standardised patient reported outcomes?  Clinical and Experimental Dermatology 2008; 33: 16-21.

Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.
Br J Dermatol. 2008; 159: 997-1035.

Gollnick HP, Finlay AY, Shear N; Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008; 9: 279-84.

Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC, Hawk JL, Sarkany RP, McMullen E, Rhodes LE, Farr PM, Anstey AV.The quality of life of 790 patients with photodermatoses. Br J Dermatol. 2008;159:192-7.

Basra MK, Edmunds O, Salek MS, Finlay AY. Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI). J Eur Acad Dermatol Venereol. 2008; 22: 813-21.

Gollnick HP, Finlay AY, Shear N. Can we define acne as a chronic disease? Am J Clin Dermatol 2008; 9: 279-284.

Finlay AY. The burden of skin disease: quality of life, economic aspects and social issues. Clin Med. 2009; 9: 592-4.

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009; 161: 987-1019.

Ingram JR, Martin JA, Finlay AY. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. Am J Clin Dermatol. 2009; 10: 229-37.

Eghlileb AM, Basra MK, Finlay AY. The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis. Dermatology. 2009; 219: 63-70.

Golics CJ, Basra MK, Finlay AY, Salek MS. Adolescents with skin disease have specific quality of life issues. Dermatology. 2009; 218: 357-66.

Potter PC, Kapp A, Maurer M, Guillet G, Jian AM, Hauptmann P, Finlay AY. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009; 64: 596-604.

Hajjaj FM, Salek MS, Basra MK, Finlay AY. Clinical decision making in dermatology: observation of consultations and the patients’ perspectives. Dermatology. 2010; 221: 331-41.

Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010;163(4):719-25.

Hajjaj FM, Salek MS, Basra MK, Finlay AY. Nonclinical influences, beyond diagnosis and severity, on clinical decision making in dermatology: understanding the gap between guidelines and practice. Br J Dermatol. 2010; 163: 789-99.

Hajjaj FM, Salek MS, Basra MK, Finlay AY. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice. J R Soc Med. 2010; 103: 178-87.

Finlay AY. Practice Gaps. Dermatologists should better integrate quality-of-life measures to inform and improve clinical decision making: comment on “The impact of pruritus on quality of life”. Arch Dermatol. 2011; 147: 1157.

Aksoy B, Altaykan-Hapa A, Egemen D, Atakan N. Indicators of health quality in 154 Turkish patients with psoriasis. J Dermatol 2011; 38(6): 600-3

Bhatti Z, Salek M, Finlay A. Chronic diseases influence major life changing decisions: a new domain in quality of life research. J R Soc Med. 2011; 104: 241-50.

Bhatti ZU, Salek MS, Finlay AY. Major life changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol. 2011; 25: 245-6; author reply 246.

Pereira FR, Basra MK, Finlay AY, Salek MS. The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology. 2012; 225: 45-53.

Katugampola RP, Badminton MN, Finlay AY, Whatley S, Woolf J, Mason N, Deybach JC, Puy H, Ged C, de Verneuil H, Hanneken S, Minder E, Schneider-Yin X, Anstey AV. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. Br J Dermatol. 2012; 167: 901-13.

Finlay AY, Basra MK, Piguet V, Salek MS. Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol. 2012; 132: 2464-5.

Finlay AY, Basra MK. DLQI and CDLQI scores should not be combined.
Br J Dermatol. 2012; 167: 453-4.

Dodington SR, Basra MK, Finlay AY, Salek MS. The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application. Br J Dermatol. 2013; 169: 31-46.

Bhatti ZU, Salek S, Finlay AY. Concept of major life-changing decisions in life course research. Curr Probl Dermatol. 2013; 44: 52-66.

Bhatti ZU, Salek SS, Bolton CE, George L, Halcox JP, Jones SM, Ketchell IR, Moore RH, Sabit R, Piguet V, Finlay AY. The development and validation of the major life changing decision profile (MLCDP). Health Qual Life Outcomes. 2013; 11: 78.

Salek MS, Jung S, Brincat-Ruffini LA, Macfarlane L, Lewis-Jones MS, Basra MK, Finlay AY. Clinical experience and psychometric properties of the Children’s Dermatology Life Quality Index (CDLQI), 1995-2012.
Br J Dermatol. 2013 May 16. doi: 10.1111/bjd.12437. [Epub ahead of print]

Golics CJ, Basra MK, Finlay AY, Salek S. The development and validation of the Family Reported Outcome Measure (FROM-16)© to assess the impact of disease on the partner or family member. Qual Life Res. 2013 Jun 25. [Epub ahead of print]

Golics CJ, Basra MK, Finlay AY, Salek S. The impact of disease on family members: a critical aspect of medical care. J R Soc Med. 2013 May 28. [Epub ahead of print]

Basra MK, Gada V, Ungaro S, Finlay AY, Salek SM. Infants’ Dermatitis Quality of Life Index (IDQoL): a decade of experience of validation and clinical application.
Br J Dermatol. 2013 Aug 2. doi: 10.1111/bjd.12563. [Epub ahead of print]

Reviews

Finlay AY. Psychological aspects of acne – an overview. Symposium Proceedings “Treating the Acne Patient: The Skin and the Psyche”. Barcelona, November 1988. Pennine Press, Cheshire, 1989.

Motley RJ, Phillips G, Finlay AY. How much disability is caused by acne? Chapter in “Acne and Related Disorders”. Ed Marks R, Plewig G. Martin Dunitz, London, 1989, p141-143.

Salek MS, Finlay AY, Khan GK, Luscombe DK. Quality of life measurement in patients with psoriasis. Chapter 48 in “Progress in Clinical Pharmacy”. Rational Use of Drugs. Proc of the 18th European Symposium on Clinical Pharmacy, Nijmegen, 1989. Editors Muller NF, Hekster YA. Amsterdam Medical Press, SDU Publishers, The Hague, 1989, p255-259.

Finlay AY. Acne : Pathogenesis, disability and treatment. Indian J Dermatol, Venereol Leprol, 1990; 56: 349-353.

Motley RJ, Finlay AY. Treat acne early and avoid disability. Mims Magazine, 1991; 18: 15.

Finlay AY. The social aspects of skin disease. Update, 1992; 44: 99-106.

Finlay AY. Quality of life impairment in atopic dermatitis and psoriasis. Clin Exp Perspectives in Sandimmum Therapy, 1992; 2: 10-11.

Finlay AY. Psychological aspects of psoriasis. Sandorama, 1992; 3: 4-8.

Finlay AY. Facing up to acne. Occupational Health, 1992; 44: 339-341.

Finlay AY. Acne Vulgaris: What are the psychological aspects? Medical Dialogue, 1992; 367: 2-3.

Finlay AY. Chair’s Summary: Disability from skin disease. Chapter in “Dermatology Progress and Perspectives. Proceedings of the 18th World Congress of Dermatology, New York, June 12-18, 1992”. Ed W.H.C. Burgdorf, S.I. Katz. Parthenon Publishing Group, New York, 1993; p1087-1089.

Finlay AY. Psychological impact of skin disease. Chapter in “Horizons in Medicine 4”, Editors CA Seymour, AM Heagarty. McGraw-Hill, London, 1993, p172-179.

Finlay AY. Effect of cyclosporin A on quality of life in psoriasis and eczema. J Dermatol Treat, 1994; 5 (Suppl 1): 513-515.

Finlay AY. Quality of Life Survey. Exchange, 1994; 73: 22.

Finlay AY. Coping with Psoriasis. BMJ, 1995; 310: 1673 (letter).

Elton B, Finlay AY. Psoriasis – it’s not a laughing matter. Dermatology in Practice, 1995, 3 (4), 5-8.

Finlay AY. Quality of life issues and economic burden of psoriasis and atopic dermatitis. Clin Drug Invest, 1995; 10, Suppl 1: 1-6.

Finlay AY. Quality of life: effects of photodamage. J Dermatol Treat, 1996; 7 (suppl 2): S9-S11.

Finlay AY, Ryan TJ. Disability and handicap in dermatology. Internat J Dermatol, 1996; 35: 305-311.

Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol, 1996; 135: 509-515.

Finlay A Y. Evaluation of Quality of Life in Dermatology: application to psoriasis. Chapter in Eipdermiology, Causes and prevention of skin disease. Eds J J Grob, R S Stern, R M Mackie, W A Weinstock. Blackwell Science, Oxford 1997.

Finlay AY. Dermatological Disability. Medicine, 1997; 25: 8: 6-7.

Finlay A Y. Quality of Life Measurement in Dermatology: a practical guide. Br J Dermatol 1997; 136: 305-314

Finlay AY. Dermatology Life Quality Index: initial experience of a simple practical measure. Chapter in: Care management of skin diseases: Life quality and economic impact. Editors: R Rajagopalan, E.F. Sherertz, R.T. Anderson. Marcel Dekker, New York, 1998 p85-94.

Finlay AY. Skin Disease Disability: measuring its magnitude. Keio Journal of Medicine, 1998; 47: 131-134.

Finlay AY. Quality of life assessments in dermatology. Seminars in Cutaneous Medicine and Surgery, 1998; 17: 291-296.

Finlay AY. Quality of life and its measurement. Chapter in “Key Advances in the Effective Management of psoriasis”. Editors: Griffiths C, Barker J. Royal Society of Medicine Press, London, 1999.

Finlay A Y. Dermatology patients: what do they really need? Clin Exp Dermatol 2000; 35: 444-450.

Finlay A Y. Psoriasis from the patient’s point of view. Arch Dermatol 2001; 137: 352-353.

Finlay A Y. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001. 45 (Suppl 1): S64-S66.

Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay AY, Leyden JJ, Shalita AR, Thiboutot D. Management of Acne. “A report from a Global Alliance to improve outcomes in acne.” J Am Acad Dermatol, 2003: 49 (Suppl. 1): S33-S35.

Working Group (including Finlay A Y). Report on the enquiry into the impact of skin diseases on people’s lives. All Party Parliamentary Group on Skin, London, July 2003.

Finlay A Y, Burgdorf W H C. Quality of life measurement in atopic dermatitis in ‘Tacrolimus ointment’. Eds: T Ruzicka, S Reitamo. Springer, Berlin 2003, P237-254.

Griffiths C E M,, Dubertret L, Ellis C N, Finlay A Y, Finzi A F, Ho V C, Johnston A, Katsambas A, Lison A-E, Naeyaert J M, Nakagawa H, Paul C, Vanaclocha F. Cicolosporin in psoriasis clinical practice: An international consensus statement.British Journal of Dermatology 2004; 150 (Suppl 67): 11-23.

Finlay A Y. Quality of Life Indices. ndian J Dermatol Venereol Leprol 2004; 70: 144-149.

Cotterill J A, Finlay A Y. General aspects of treatment. Chapter 71 in Rook Textbook of Dermatology, Editors – T Burns, S Breathnach, N Cox, C Griffiths. Blackwells Science, Oxford, 2004.

Finlay A Y. Current severe psoriasis and their Rule of Tens. BJD 2005; 152: 861-867.

Lewis V J, Finlay A Y. Two Decades Experience of the PDI. Dermatology 2005; 210: 261-268.

Katugampola R P, Finlay A Y. Impact of skin diseases on quality of life. vChapter 2.7 in P Fritsch, W Bergdorf (Editors). EDF White Book, Skin Disease in Europe 2nd Edition Berlin 2005, ABW Wissenschaftverlag.

Lewis V J, Finlay A Y. A critical review of quality of life scales for psoriasis. Dermatol Clin 2005; 23(4): 707-716.

Lewis V J, Ortonne J-P. Patient satisfaction with psoriasis therapies: an update and introduction to biological therapy. J Cutan Med Surg 2005 (May 5: e-pub). Sept – Oct 2004; 8(5): 310-320.

Smith S H, Anstey A V, Barker J N W N, Burren A D, Chalmers R J G, Chandler D, Finlay A Y, Griffiths C E M, Jackson K, McHugh N J, McKenna K E, Reynolds N J, Ormerod A D. British Association of Dermatologist Guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.

Finlay A Y. Research methodology in quality of life assessment. Chapter 9 in Psychodermatology, the psychological impact of skin disorders.Editors C Walker, L Papadopoulos. Cambridge University Press, Cambridge 2006.

Finlay A Y. The burden of atopic eczema. Chapter 4 in Handbook of Atopic Eczema, 2nd Edition Eds J Ring, B Przybilla, T Ruzicka. Springer-Verlag, Berlin 2006 P31-36.

Finlay A Y. Uni – dimensionality of the DLQI – confirmed at last. Acta Dermato-Venereologica 2005; 85: 385.

Finlay A Y. The Dermatology Life Quality Index. MIMS Dermatology 2006; 2: 12.

Griffiths C E, Katsambas A, Dijkmans B A, Finlay A Y, Ho V C, Johnston A, Luger T A, Mrowietz U, Thestrov-Pedersen K. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 2006; 155 (Suppl 2): 1-16.

Dalgard F, Finlay A Y.  Need and greed in dermatology:  disease and outcome measures in dermatological healthcare planning.  Dermatology 2006; 213: 279-283

Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.

Katugampola RP, Finlay AY. Impact of skin diseases on quality of life. Eur J Dermatol. 2007; 17: 102-6.

Finlay AY, Reich K. Outcome assessment and treatment goals. Expert Reviews in Dermatology 2008; 3 (4Suppl 1) S39-40.

Yan H, Li W, Finlay AY. Measures of disease severity and life quality in patients with psoriasis. Int J Dermatol Venereol 2009; 35: 306-8.

Greaves MW, Munro CS, Finlay AY. Dermatology: the last 30 years – a rollercoaster ride. Clinical Medicine 2009; 9: 588-594.

Finlay AY, Smith CH. General aspects of treatment. Chapter 72 in Rook’s Textbook of Dermatology, 8th edition. Editors DA Burns, SM Breathnach, NH Cox, CEM Griffiths. 2010 Blackwell publishing, Oxford.

Bhatti ZU, Salek S, Finlay AY. Concept of major life-changing decisions in life course research. Current Problems in Dermatology 2013; 44: 52-66.

Abstracts

Finlay AY, Kelly SE. Psoriasis: an Index of Disability. Scot Med J, l985; 30: 266.

Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Br J Dermatol, 1990; 123 (Suppl. 37): 21-22.

Finlay AY, Salek MS, Khan GK, et al. Quality of life improvement in cyclosporin treated atopic dermatitis patients – a double-blind crossover study. (Prize for Best Presentation). Br J Dermatol, 1991; 125 Suppl. 38: 16.

Salek MS, Finlay AY, Khan GK, Luscombe DK. Quality of Life in Pharmacotherapy: Reliability and Validity of a General Self-Scored Questionnaire. Pharmaceutisch Weekblad Scientific Edition 92; 14(4) Suppl E: E23.

Finlay AY, Khan GK. The Dermatology Life Quality Index: A simple practical measure for routine clinical use. Br J Dermatol, 1993; 129, Suppl 42: 27.

Salek MS, Finlay AY. Cyclosporin improves quality of life in psoriasis – Does this matter? Br J Dermatol, 1993; 129, Suppl 42: 32.

Herd RM, Tidman MJ, Hunter JAA, Prescott R, Finlay AY, Rutta D. The Lothian atopic dermatitis community study: prevalence, cost and effect on quality of life. Br J Dermatol, 1994; 131, Suppl 44: 24.

Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporin in severe childhood atopic dermatitis: a multicentre study. Br J Dermatol, 1994; 131, Suppl 44: 25.

Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI). Br J Dermatol, 1994; 131, Suppl 44: 26.

Herd RM, Tidman MJ, Hunter JAA, Prescott R, Finlay AY.The economic burden of atopic eczema: a community and hospital based assessment. Br J Dermatol, 1994; 131, Suppl 44: 34.

Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol, 1994; 131, Suppl 44: 37.

Kurwa HA, Ashcroft R, Dickinson B, Finlay AY. Dermatology inpatient admission greatly improves life quality. J Dermatol Treat, 1994; 5(4): 248. J. Eur. Acad. Dermatol Venereol, 1995; 5, Suppl.1: S83.

Blackford S, Roberts DL, Salek MS, Finlay AY. Basal cell carcinomas and their treatment cause little handicap – the reason for delayed presentation? J Dermatol Treat, 1994; 5(4): 248. J. Eur. Acad. Dermatol Venereol, 1995; 5, Suppl.1: S116.

Finlay AY. Quality of life – effects of photodamage. Dermatology, 1995; 190: 262

Salek MS, Finlay AY, Berth-Jones J et al. Effect of cyclosporin on quality of life in severe childhood eczema. J. Eur. Acad. Dermatol Venereol, 1995; 5, Suppl.1: S89-S90.

Finlay AY. Evaluation of disability in psoriasis. Les Nouvelles Dermatologiques, 1995; 14 (Suppl 1): 47-48.

Lawson V, Lewis-Jones MS, Reid P, Owens RG, Finlay AY. Family impact of childhood atopic eczema. Br J Dermatol, 1995; 133 Suppl 45: 19. J. Eur. Acad. Dermatol Venereol, 1995; 5, Suppl.1: S101.

Mallon E, Newton JN, Klassen A, Ryan TJ, Finlay AY. Standard patient-assessed quality of life instruments can be used to measure the benefits of acne treatment. Br J Dermatol, 1995; 133 Suppl 45: 35.

Blackford S, Roberts DL, Finlay AY. What is the impact on quality of life of the skin manifestations of Behcet’s syndrome? Br J Dermatol, 1995; 133 Suppl 45: 35-36.

Harris AJ, Burge SM, Finlay AY. Quantifying disability in Darier’s Disease. Br J Dermatol, 1995; 133 Suppl 45: 43.

Lewis-Jones MS, Lawson V, Hill G, Reid P, Owens G, Finlay AY. Monitoring childhood skin disease handicap. Br J Dermatol 1996; 135, Suppl 47: 52.

Finlay AY. The effect of acne on the quality of life. J Invest Dermatol, 1997; 108: 390 Williamson D, Gonzalez M, Finlay AY.Quality of life in patients with hair loss. Br J Dermatol, 1997: 137 Supplement 50, 47.

Clark SM, Goulden V, Finlay AY, Cunliffe WJ. The psychological and social impact of acne: a comparison study using three acne disability questionnaires. Br J Dermatol, 1997: 137 Supplement 50, 41.

Salek MS, Finlay AY, Sumner MJ. Intermittent short course cyclosporin (neoral) improves quality of life (QOL) in psoriasis.Austral J Dermatol, 1997, 38, Suppl 2, 108.

Salek MS, Finlay AY, Sumner MJ. Quality of life impact of long term cyclosporin in severe adult atopic dermatitis – an open multicentre study. Austral J Dermatol, 1997, 38, Suppl 2, 240.

Ahmed I, Berth-Jones J, Friedmann P, Graham-Brown R, Cork M, Sowden J, Finlay A, Beard A, Sumner M, Harper JI. Short course versus continuous course therapy of cyclosporin in severe childhood atopic dermatitis. British Journal of Dermatology, 1998; 139 (Suppl 51): 22.

Finlay AY, Coles EC, Lewis-Jones MS et al. Quality of life improves after seeing a dermatologist. Br J Dermatol 1998; 139 (Suppl 51): 15.

Finlay AY, Lewis-Jones MS, Sharp JL, Dykes PJ. Children’s Dermatology Life Quality Index: cartoon version validation.Br J Dermatol 1998; 139 (Suppl 51): 67-68.

Harlow D, Poyner T, Finlay AY, Dykes PJ. High impairment of quality of life of adults with skin diseases in primary care. Br J Dermatol 1998; 139 (Suppl 51): 15.

Lewis-Jones MS, Finlay AY, Hill G, Dykes PJ. The impact of atopic dermatitis on children and their families: a community study. 8th International Congress Pediatric Dermatology. Annals de Dermatologie et de Venereologie, 1998; 125 (Suppl 1): S62.

Helland CA, Hermansen SE, Finlay AY. Doctor’s perception of patients’ quality of life impairment. J Eur Acad Derm Vener, 1998; 11 (Suppl 2): S257.

Grosshans E et al. Adapalene 0.1% gel has a more rapid onset of action than tretinoin 0.025% gel in the treatment of acne vulgaris. J Eur Acad Derm Vener 1998; 11 (Suppl 2), S99.

Ayyalaraju RS, Finlay AY, Kirsner RS, Trent JT, Kerdel FA. Dermatology inpatient services: A UK/USA Comparative Study. Br J Dermatol 1999; 141 (Suppl 55): 79-80.

Mufleh L, Gonzalez M, Judodihardjo H, Finlay AY. Compliance is high in patients taking oral isotretinoin for acne. British Journal of Dermatology. Br J Dermatol 1999; 141 (Suppl 55): 87.

Zaghloul S, Gonzalez M, Judodihardjo H, Finlay AY. The greater the disability, the poorer the topical treatment compliance.Br J Dermatol 1999; 141 (Suppl 55): 48.

Lewis-Jones MS, Finlay AY, Dykes PJ. Measurement of the impact of atopic dermatitis on infant’s and their families lives. Br J Dermatol 1999; 141 (Suppl 55): 105-106.

Ayyalaraju RS, Finlay AY, Dykes PJ, Trent JT, Kerdel FA, Kirsner RS. Dermatology inpatient services: A UK / USA comparative study. J Invest Dermatol 2000; 114: 886.

Lanigan S W, Kwan C K, Dykes P J, Gonzalez M. Quality of life studies in hirsute women receiving ruby laser treatment. Br J Dermatol 2000: 143 (Suppl 57) 42-85.

Al-Awadi R, Dykes P J, Gonzalez M, Finlay A Y. Life activity impairment by skin disease. J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1): 54.

Aledan M, Gonzalez M, Finlay A Y. Utility measure development for children with skin disease. J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1): 281.

Finlay A Y, Corvest M, Lefrancois P, Taieb C. The French version of the psoriasis disability index. JEADV 2001; 15 (Suppl 2): 250.

Finlay A Y, Corvest M, Lefrancois P, Taieb C. Psoriasis and current life: preliminary results on 527 subjects. JEADV 2001; 15 (Suppl 2): 244.

Dreno B, Finlay AY, Corvest M et al. Follow-up psoriasis-observation and therapy: French initiative. JEADV 2001; 15 (Suppl 2): 238.

Finlay AY. Impact of quality of life impairment on compliance. Ann Dermatol Venereol 2002; 129: IS182.

Diba VC, Loo W-J, Chawla M, Finlay AY. Dermatology Life Quality Index (DLQI): Validation of an illustrated version. Ann Dermatol Venereol 2002; 129: IS254-253. Lewis-Jones MS, Finlay AY. Measuring quality of life in children. Ann Dermatol Venereol 2002; 129: IS684.

Dreno B, Finlay AY, Corvest M, Lefrancois P, Myon E, Taieb C. Psoriasis disability is related to length of history of psoriasis.Ann Dermatol Venereol 2002; 129: IS753.

Finlay AY, Corvest TM, Lefrancois P Taieb C. Psoriasis and everyday life: first results on 1,866 subjects. Ann Dermatol Venereol 2002; 129: IS755.

Finlay AY, Corvest TM, Lefrancois P Taieb C. The French version of the Psoriasis Disability Index. Ann Dermatol Venereol 2002; 129: IS755.

Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147 (Suppl 62): 50.

Finlay A Y, Corvest M, Lefrancois P, Myon E, Taieb C H. Psoriasis and everyday life: first results on 1866 subjects. JEADV 2002; 16 (Suppl 1): 292.

Dreno B, Finlay A Y, Corvest M, Lefrancois P, Myon E, Taieb C. Psoriasis disability is related to the length of history of psoriasis. JEADV 2002; 16 (Suppl 1): 292. Finlay A Y, Myon E, Taieb C. Immoderate exposure to the sun: short-term impact on quality of life. JEADV 2003; 17 (Suppl 3):62.

Taieb C, Myon E, Perez N, Finlay A Y. Quality of life and atopic dermatitis: annual assessment in France. JEADV 2003; 17(Suppl 3): 61. A Y Finlay, Del Molino J M, Conesa A, Myon E, Taieb C. Psoriasis and quality of life: Spanish results.JEADV 2003; 17(Suppl 3): 62

Finlay A Y, Dreno B, Nocera T, Verriere F, Myon E, Taieb C. The French version of the Cardiff Acne Disability Index.JEADV 2003; 17(Suppl 3): 62.

Finlay A Y. What do quality of life scores really mean? JEADV 2003; 17(Suppl 3): 58.

Myon E, Finlay A Y, Dreno B, Corvest M, Lefrancois P Taieb C. A national survey of quality of life in patients with psoriasis.JEADV 2003; 17(Suppl 3): 59.

Hongbo Y, Harrison M A, Salek S S, Finlay A Y. Assessing the meaningfulness of Dermatology Life Quality Index (DLQI).JEADV 2003; 17(Suppl 3): 113.

Taieb C, Finlay A Y, Lefrancois P, Myon E. Psoriasis: Quality of life according to gender. JEADV 2003; 17(Suppl 3): 375.

Taieb C, Finlay A Y, Delmolino J, Conesa A, Myon E. Psoriasis and quality of life: Spanish results. JEADV 2003; 17(Suppl 3): 375.

Myon E, Finlay A Y, Lefrancois P, Taieb C. Duration of psoriasis and quality of life. JEADV 2003; 17(Suppl 3): 376.

Taieb C, Finlay A Y, Lefrancois P, Myon E. Psoriasis and quality of life SPOT study: results at 3 months. JEADV 2003; 17(Suppl 3): 376.

Hongbo Y, Harrison M A, Salek M S, Finlay A Y. What do the Dermatology Life quality Index (DLQI) scores really mean in terms of patients’ overall quality of life. Qual Life Research 2003; 12: 778.

Hongbo Y, Thomas C L, Harrison M A, Salek M S, Finlay A Y. Translating the science of quality of life into practice. What do dermatology life quality index scores mean? Br J Dermatol 2004; 151 (Suppl 68): 45-46.

Lewis V J, Finlay A Y. Two decades’ experience of the Psoriasis Disability Index. Br J Dermatol 2004; 151 (Suppl 68): 50-51.

Katugampola R P, Hongbo Y, Finlay A Y. The relationship between patient-rated quality of life and clinicians’ management decisions in psoriasis – A prospective study. J Invest Dermatol 2004; 123 (2): A70.

Salek S, David S, Ahmed Z, Finlay A Y. An evaluation of the relevance of HRQoL discussion in out-patient consultation to the level of impairment as measured by the DLQI. Quality of Life Research 2004; 13: 1522.

Taieb C, Finlay A Y, Myon E, Del Molino J. Psoriasis and quality of life: Spanish results. JEADV 2004; 18: 775.

Taieb C, Finlay A Y, Myon E. Duration of psoriasis and quality of life. JEADV 2004; 18: 775. Taieb C, Finlay A Y, Myon E.Psoriasis: quality of life according to gender. JEADV 2004; 18: 785.

O’Donnell R A, Finlay A Y, Niziol C. The impact of psoriasis on productivity: a survey of psoriasis patients in the UK.JEADV 2004; 18: 788.

Katugampola R P, Hongbo Y, Finlay A Y. Patient centred management decisions for psoriasis. JEADV 2004; 18: 789-790.

Taieb C, Finlay A Y, Nocera T, Verriere F, Martin N, Myon E. Impact of hydrotherapy programme on the quality of life of patients suffering from psoriasis. JEADV 2004; 18: 811.

Ahmed Z, David S, Salek M S, Finlay A Y. Is there a relationship between the DLQI scores and quality of life related discussions in dermatology out-patient clinic consultations? JEADV 2004; 18 (Suppl 2): 535.

Finlay A Y, Myon E, Martin N, Verriere F, Taieb C. Impact of thermal spa on children’s quality of life. JEADV 2004; 18 (Suppl 2): 310.

Katugampola R P, Hongbo Y, Finlay A Y. Are clinical management decisions related to the impact of psoriasis on patient-rated quality of life? JEADV 2004; 18 (Suppl 2): 156.

Katugampola R P, Hongbo Y, Finlay A Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. BJD 2005; 152: 1256-1262.

Lewis V J, Finlay A Y. Quality of life scale – A critical review. British Epidermo-Epidemiology Society 14th Annual Meeting, Cardiff March 2005. British Journal of Dermatology 2005: 153: 476

Katugampola R P, Thomas C L, Hongbo Y, Salek M S, Finlay A Y. Psoriasis decision taking and the DLQI bands. British Epidermo-Epidemiology Society 14th Annual Meeting, Cardiff March 2005. British Journal of Dermatology 2005: 153: 475-476.

Katugampola R, Hongbo Y, Finlay A Y. Patient rated quality of life and clinicians’ management decisions over psoriasis: a prospective study. Presentation at American Academy of Dermatology Annual Meeting, New Orleans, Feb 2005. J Am Acad Dermatol 2005; 52 (Suppl 1): P 105 (Poster 1314).

Thomas C, Hongbo Y, Salek S, Finlay A Y. A Global question approach to aid interpretation of DLQI scores. Presentation at American Academy of Dermatology Annual Meeting, New Orleans, Feb 2005. J Am Acad Dermatol 2005; 52 (Suppl 1): P 102 (Poster 1301).

Taieb C, Finlay A Y, Nguyen C, Myon E. Adults with atopic dermatitis: quality of life impact. Presentation at American Academy of Dermatology Annual Meeting, New Orleans, Feb 2005. J Am Acad Dermatol 2005; 52 (Suppl 1): P 66 (Poster 700).

Taieb C, Finlay A Y, Nguyen C, Myon E. Atopic dermatitis: impact on husbands and wives. Presentation at American Academy of Dermatology Annual Meeting, New Orleans, Feb 2005. J Am Acad Dermatol 2005; 52 (Suppl 1): P 100 (Poster 203).

Finlay A Y, Ortonne J-P, Henninger E. Clinical relevant of improvement in quality of life in psoriasis patients, receiving efalizumab. European Academy of Dermatology & Venereology. 3rd Spring Symposium, Sophia, Bulgaria 19-22 May 2005.

Finlay A Y. Decision taking in psoriasis and quality of life. Quality of life in Dermatology Workshop. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM)

Davies E, Patel C, Salek M S, Finlay A Y. Quality of life discussions in patients with inflammatory skin disease. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM)

Davies S H, Finlay A Y. Psoriasis: Management decision in women. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM)

Lewis V J, Finlay A Y. A review of the use of the DLQI in assessing efficacy of the biological therapies in psoriasis. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM)

Eghlileb A. Davies E, Finlay A Y. Impact of psoriasis on partner’s and family’s quality of life. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM).

Melilli L E, Zhong J, Hoffman R, Finlay A Y. Rapid reduction in disease impact with Adalimumab treatment in patients with moderate to severe chronic plaque psoriasis. 14th Congress of EADV. London, October 2005 JEADV 2005; (CD ROM).

Basra M K A, Finlay A Y, Sue-Ho R. The family impact of skin diseases. 14th Congress of EADV. London, October 2005. JEADV 2005; (CD ROM).

Salek M S, Varma K, Finlay A Y. Minimal clinical important changes of quality of life scores in dermatology. 14th Congress of EADV. London , October 2005. JEADV 2005; (CD ROM).

Salek M S, Patel C, Davies E, Finlay A Y. Are dermatology outpatient clinic consultations patient-centred? 12th Annual Conference of the International Society for Quality of Life Research, San Francisco, CA, USA October 2005. Quality of life Research 2005; 14: 2045.

Basra M, Finlay A Y. Family Dermatology Life Quality Index: Conceptualization of a novel dermatology-specific outcome measure for the families of dermatological patients. JAAD 2006; 54(3) Suppl AB118.

Davies E, Patel C, Salek S Finlay A Y. Quality of life discussion and patient satisfaction in inflammatory skin disease consultations. JAAD 2006; 54(3) Suppl: AB120.

Eghlileb A, Davies E, Finlay A Y. Psoriasis has significant impact on relatives and partners of patients with psoriasis. JAAD 2006; 54(3) Suppl: AB206.

Melilli L , Zhong J, Finlay A Y. Rapid improvement in functional limitations of patients with moderate to severe chronic plaque psoriasis treated with Adalimumab. JAAD 2006; 54(3) Suppl AB223

Basra M K A, Su-Ho R, Finlay A Y. Psychometric properties of the Family Dermatology Life Quality Index (FDLQI): A novel dermatology-specific quality of life measure for the families of dermatology patients. Br J Dermatol 2006; 155 (Suppl 1): 7 (p1-9).

Katugampola R, Lewis V J, Finlay A Y. A review of the Dermatology Life Quality Index in assessing the efficacy of biological treatments in psoriasis. Br J Dermatol 2006; 155 (Suppl 1): 34 (p21-61)

Eglileb A, Davies E E G, Finlay A Y. The secondary impact of psoriasis on the family: The Psoriasis Family Index. Br J Dermatol 2006; 155 (Suppl 1): 31 (p21-61).

Basra M K, Finlay A Y. Development and evaluation of the Family Dermatology Life Quality Index. J Investig Dermatol 2006; 126 (Suppl 3):s105.

Finlay A Y.  The secondary impact of skin disease – the unrecognised family effect.  Workshop:  The Burden of Skin Disease on Quality of Life.  15th Congress EADV, Rhodes, 7 October 2006.  Abstracts CD W27.8

Basra M M K, Finlay A Y.  Eczema has greater impact than psoriasis on the quality of life of the patient’s family.  15th Congress EADV, Rhodes, 7 October 2006.  Abstracts CD   FC20.1

Roberts A W, Salek M S, Finlay A Y.  Can patient reported outcomes help to improve treatment decision taking in dermatology out-patients?  15th Congress EADV, Rhodes, 7 October 2006
Abstracts CD  PO12.13

Thomas C L , Finlay A Y.  Measuring the effects of psoriasis on quality of life.  Expert Review of Dermatology 2006; 1(5):  723-726

Basra M, Finlay A Y.  Eczema has greater impact then acne on the quality of life of patient’s families.  65th Annual Meeting of American Academic of Dermatology, Washington DC, 2-6 February 2007.  Journal of American Academy of Dermatology 2007; 56 (Suppl 2): AB102 (P1300)

Basra M K A, Finlay A Y.  Inflammatory skin diseases cause greater impairment of patient’s families’ quality of life than non-inflammatory disease or isolated skin lesions.  European Academy of Dermatology & Venereology Annual Meeting.  Vienna, Austria, 16-20 May 2007 P 394

Basra M K A, Finlay A Y.  Family quality of life:  does it depend on gender?  EADV Annual Meeting, Vienna, Austria.  16-20 May 2007 P395

Finlay AY.  Life quality impact – Every clinician’s concern.  The Albert Neisser Lecturer 2007 Department of Dermatology Wroclaw University, Wroclaw Poland, 14 June 2007.  12th Congress of the European Society for Dermatology & Psychiatry. Dermatologia Kliniczna 2007; 9 (Supple 1/07): 14-15

Eghlileb AM, Finlay A Y.  Assessment of patient’s psoriasis severity by relatives and partners.  2nd International Congress on Psoriasis, 21-24 June 2007, Paris, France.  Journal of the European Academy of Dermatology & Venereology 2007; 21 (Suppl 1): 30

Eghlileb AM, Basra M K A, Finlay A Y.  Initial validation and refinement of the Psoriasis Family Index.  87th Annual Meeting of BAD, Birmingham, 10-13 July 2007.  British Journal of Dermatology 2007; 157 (Suppl 1) 54 (23-73)

Basra M K A Finlay A Y.  Quality of life of patients and their families is related to the self-assessed severity of patient’s skin disease.  87th Annual Meeting of BAD, Birmingham, 10-13 July 2007.  British Association of Dermatologists 2007; 157 (Suppl 1): 56 (23-73)

Jong C T, Finlay A Y, Anstey A V, Pearse A D, Kerr A C, Ferguson J, Benton E C, Hawk J L M, Sarkany R P, McMullen E, Rhodes L E, Farr P M.  The quality of life of 797 patients with photodermatoses.  87th Annual Meeting of BAD, Birmingham, 10-13 July 2007.  British Association of Dermatologists 2007; 157 (Suppl 1) 10-11 (10-13)

Basra M K A, Finlay A Y.  Age, gender, disease duration or self-assessed disease severity:  which is the best predictor of dermatological patients’ quality of life?  37th ESDR Meeting.  Journal of Investigative Dermatology 2007; 127 (Suppl 2): S29 (abstract 171)

Basra M K A, Finlay A Y.  Dermatology quality of life and patient’s age.  21st World Congress of Dermatology, Buenos Aires, Argentina 2007.  Poster Abstract Book 2, p640 (Poster 5926)

Basra M K A, Finlay A Y.  The family impact of skin diseases:  the role of patient’s age.  21st World Congress of Dermatology, Buenos Aires, Argentina 2007.  Poster Abstract Book 2, p641 (Poster 5927)

Finlay A Y.  Measuring the impact of cosmetics on quality of life.  Symposium:  the real benefit of cosmetics:  their efficacy in quality of life and well-being.  21st World Congress of Dermatology, Buenos Aires, Argentina 2007.  Abstract Book 1, p304-5 (1708)

Finlay A Y.  Understanding the impact of psoriasis on the patient and the family – ‘The Greater Patient’  Meeting of Minds Symposium ‘Psoriasis at the XX1 Century:  the birth of patient based medicine’  21st World Congress of Dermatology, Buenos Aires, Argentina 2007.  Abstract Book 1, p320-321 (1805)

Finlay A Y.  The Greater Patient:  the secondary family impact of skin disease.  Symposium ‘The burden of skin disease’.  21st World Congress of Dermatology, Buenos Aires, Argentina 2007.  Abstract Book 1, p565 (3089)

Basra M K A, Finlay A Y.  Determinants of family quality of life in dermatology.  14th Annual Conference International Society for Quality of Life Research.  Toronto, Canada, 10-13 October 2007
Quality of Life Research 2007; ISOQOL Conference & Abstract Issue (Suppl 1): A-112

Salek S, Edmunds O, Basra M K A, Finlay A Y.  Assessing the convergent validity of a questionnaire used to measure the quality of life of family members of dermatology patients.  Toronto, Canada 10-13 October 2007.  Quality of Life Research2007;      (Suppl 1): A-92

Eghlileb A M, Finlay A Y.  Responsiveness of the Psoriasis Family Index (PFI-20) instrument to treatment of the family member’s psoriasis.  Toronto, Canada 10-13 October 2007.  Quality of Life Research 2007;       (Suppl 1): A-61

Basra MK, Finlay AY.  The Dermatology Life Quality Index (DLQI) is a unidimensional instrument: further data in support. J Invest Dermatol 2008; 128: S80.

Eghlileb AM, Finlay AY. Further validation of Psoriasis Family Index (PFI-15): a new measure to assess the secondary impact of psoriasis on family members. Br J Dermatol 2008; 159 (Suppl 1): 48.

Basra M, Finlay AY. The impact of skin diseases on the parents and spouses/partners of the patients: a descriptive analysis. Br J Dermatol 2008; 159 (Sippl 1): 48-49.

Hajjaj FM, Basra M, Salek S, Finlay AY. Influences of clinical decision-making in dermatology outpatient clinics. Br J Dermatol 2008; 159 (Suppl 1): 49-50.

Katugampola RP, Badminton MN, Finlay AY et al. Congenital erythropoietic porphyria: a genotype/phenotype correlation and health-related quality of life study of 27 unrelated cases. Br J Dermatol 2008; 159 (Suppl 1): 7-8.

Golics CJ, Basra MKA, Finlay AY, Salek MS. Do adolescents with skin disease have specific quality of life issues?  J Invest Dermatol 2008; 128: 2549.

Hajjaj FM, Basra M, Salek MS, Finlay AY.  Clinical decision taking in dermatology: the role of clinical and non-clinical factors. J Invest Dermatol 2008; 128: 2550.

Bhatti ZU, Finlay AY, Salek S. Chronic skin diseases influence major life-changing decisions: a new frontier in health outcomes research.  Br J Dermatol 2009; 161 (Suppl 1): 58-59.

Hajjaj F, Basra MK, Salek S, Finlay AY. Nonclinical influences on clinical decision making in dermatology. Br J Dermatol 2009; 161 (Suppl 1): 59.

Finlay AY. The Greater Patient and sharing decisions. Acta Dermato-Venereologica 2009; 89: 569-570.

Basra MK, Sturkey RL, Salek MS, Finlay AY. Dermatology Life Quality Index: measuring the change in scores and its clinical meaningfulness. J Invest Dermatol 2009; 129 (Suppl 2): S30.

Salek S, Sturkey R, basra M, Finlay AY. Determining the minimal important difference for the Dermatology Life Quality Index. Quality of Life Research 2009 (October). A-37.

Salek S, Mahbouba T, Basra M, Golics C, Finlay A. Development and validation of a health-related quality of life measure for adolescents with skin diseases. Quality of Life Research 2009. (October). A-92.

Bhatti ZU, Finlay AY, Salek S, Ketchell RI, Bolton CE. Chronic respiratory diseases strongly influence major life-changing decisions. Thorax 2009; 64 (Suppl 4): A109-A114.

Bhatti ZU, Finlay AY, Salek MS, George LD. Diabetes influence on major life changing decisions: should this be an area of concern in management of patients? Diabetic Medicine 2010; 27 (Suppl 1): 1-36.

Bhatti ZU, Salek SS, Finlay AY, Jones SM. Better understanding of the influence of rheumatic disorders on major life changing decisions. Annals of the Rheumatic Diseases 2010; 69 (Suppl3): 715.

Bhatti ZU, Salek S, FinlayAY. The influence of chronic skin diseases on major life-changing decisions as a parameter for the assessment of long-term impact. Br J Dermatol 2010; 163; (Suppl 1): 39-40.

Basra MKA, Camilleri L, Salek S, Finlay AY. Strengthening the Dermatology Life Quaity Index’s clinical meaning: minimal clinically important difference of the scores. Br J Dermatol 2010; 163 (Suppl 1): 41.

Hajjaj F, Salek S, basra MKA, Finlay AY. Nonclinical influences in dermatology decision making: a study of clinicians’ perspective. Br J Dermatol 2010; 163 (Suppl 1): 44-45.

Bhatti ZU, Finlay AY, Salek MS, Halcox JJ.  The full impact of chronic cardiovascular diseases cannot be measured without an assessment of life decisions.  The Journal of Heart Disease 2010; 7 (1): 71.

Finlay AY, Basra MKA. The secondary impact of skin disease on the Greater Patient. Quality of Life Research 2010; 19 (Suppl 1): 101-102.

Finlay AY, Basra MKA. How skin disease affects the Greater Patient. Acta Derm Venereol 2011; 91: 219.

Finlay AY, Hajjaj FM, Basra MKA, Salek MS. Non-clinical influences in the dermatology consultation: the doctor’s perspective and the challenge to evidence based practice. Acta Derm Venereol 2011; 91: 224.

Basra MKA, Salek MS, Fenech D, Howe A, Mahbouba T, Golics CJ, Finlay AY. Measuring skin disease in adolescence: bridging the gap in quality of life assessment. Acta Derm Venereol 2011; 91: 219.

Golics CJ, Basra MKA, Salek MS, Finlay AY.  The impact of disease on the lives of family members. Acta Derm Venereol 2011; 91: 219.

Bhatti ZU, Salek MS, Finlay AY.  The influence of skin disease on major life changing decisions. Acta Derm Venereol 2011; 91: 221.

Bhatti ZU, Salek S, Finlay AY. Development of the major life changing decisions profile: a novel approach to measure the long-term impact of disease. Br J Dermatol 2011; 165 (Suppl 1): 52.

Finlay AY, Hajjaj FM, Salek MS, Basra MKA. Non-clinical influences on decision taking in dermatology clinics. J Invest Dermatol 2011; 131 (Suppl 2): S116-S117.

Golics C, Basra M, Salek S, Finlay AY. Diseases profoundly affect the quality of life of family members of patients. J Invest Dermatol 2011; 131 (Suppl 2): S39.

Basra M, Zammit AM, Salek S, Finlay A. Application of Rasch analysis to Psoriasis Family Index (PFI) – a novel psoriasis-specific quality of life instrument for family members and partners of psoriasis patients. J Invest Dermatol 2011; 131 (Suppl 2): S49.

Basra M, Salek S, Taweer Z, Fenech D, Howe A, Mahbouba T, Golics C, Piguet V, Finlay A. Refinement and validation of Teenager’s quality of life questionnaire (T-QoL). J Invest Dermatol 2011; 131 (Suppl 2): S50.

Golics CJ, Basra MKA, Salek MS, Finlay AY.  The Family Reported Outcome Measure (R): initial validation of a generic QoL measure for family members of patients with chronic medical conditions. J Invest Dermatol 2012: 132, S72.

Pereira FRA, Basra MKA, Piguet V, Finlay AY, Salek MS.  The role of the EQ-5D questionnaire in the economic evaluation of dermatological conditions and therapies. J Invest Dermatol 2012; 132: S72.

Salek MS, Basra MKA, Cruz P, Piguet V, Finlay AY.  Comparison of the DLQI and EQ-5D for use in economic studies of dermatological treatments.  J Invest Dermatol 2012; 132: S72.

Basra MK, Salek S, Finlay AY. Minimal clinically important difference (MCID) of the Dermatology Life Quality Index (DLQI) scores and responsiveness to change in inflammatory dermatoses. J Invest Dermatol 2013; 133 (Suppl 1): S95.

Basra MK, Finlay AY, Salek S.  Development and validation of teenagers’ quality of life (T-QoL ©) Index: a dermatology-specific measure for adolescents. J Invest Dermatol 2013; 133 (Suppl 1): S95.

Finlay AY. The cumulative life course impairment. J Eur Acad Dermatol Venereol 2013; 27 (Suppl 4), July 2013 (on disc)

 

QOL

Further Information

For general queries, technical aspects and permission to use:

E-mail: dermqol@cf.ac.uk

Other contacts:

Mrs Joy Hayes (financial aspects):
HayesJ@cf.ac.uk

Professor Andrew Y Finlay:
FinlayAY@cf.ac.uk

Address:
Department of Dermatology
Cardiff University School of Medicine
Heath Park, Cardiff
CF14 4XN
United Kingdom
Tel: +44 (0)29 2074 2884
Fax: +44 (0)29 2074 4321

FAQs

Quality of Life FAQs

Publications

Key References
Full Reference List